AI Insight
This retrospective cohort study analyzed 14 years of methylphenidate prescription data for 23,243 children with ADHD in South Africa's Western Cape public health system. Only 28.2% of children remained on treatment after 12 months of initial prescription, and 15.4% after restarting treatment—rates substantially lower than those reported in high-income countries. Frequent early medical visits and access to sustained-release formulations were the strongest predictors of continued medication use, while nearly 40% of patients cycled through three or more treatment episodes.
Why it matters
These findings reveal significant treatment discontinuation challenges in a lower-resource setting, suggesting that clinical engagement strategies and reducing access barriers could improve ADHD medication persistence. The research provides rare evidence from Africa on long-term stimulant medication patterns, highlighting disparities between high-income and middle-income healthcare systems in managing chronic childhood conditions.
Understand the Science
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Background Persistence with stimulant medication is poor in children and adolescents with ADHD, and the evidence base is derived predominantly from high-income countries. We describe methylphenidate utilisation patterns and predictors of 12-month retention across 14 years in a large South African public health service. Methods Retrospective cohort study using routine pharmacy data from the Western Cape provincial health service (2011-2024). Children aged 5-18 at first prescription were included. Treatment episodes were defined as continuous prescription sequences with no gap exceeding 90 days and classified as initiations or restarts. Logistic regression modelled 12-month retention against early visit frequency and formulation type as pre-specified exposures. Findings 421,925 prescription events for 23,243 children across 115 facilities generated 65,885 treatment episodes. Median age at first prescription was 10 years (IQR 8-12); 77.6% were male. Kaplan-Meier 12-month survival was 28.2% for initiations and 15.4% for restarts, substantially below high-income country comparators. A quarter of all initiating prescriptions were not followed by a subsequent dispensing event; nearly 40% of patients had three or more treatment episodes. Early visit frequency was the strongest predictor of 12-month retention (high vs low: OR 2.85, 95% CI 2.65-3.06). The sustained-release formulation effect was present but attenuated on multivariable adjustment. Treatment re-initiations showed a marked seasonal pattern consistent with the South African school calendar. Interpretation Twelve-month retention was markedly lower than high-income country rates. Against a backdrop of high attrition, both early visit frequency and sustained-release formulation access predicted persistence; clinical engagement and reducing structural barriers to access are modifiable factors in this setting. Funding None.